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1
The strongest genetic risk factors for primary sclerosing cholangitis (PSC) are found in the
human leukocyte antigen (HLA) complex at chromosome 6p21. Genes in the HLA class II
region encode molecules that present antigen to T lymphocytes. Polymorphisms in these genes
are associated with most autoimmune diseases, most likely because they contribute to the spec-
iﬁcity of immune responses. The aim of this study was to analyze the structure and electro-
static properties of the peptide-binding groove of HLA-DR in relation to PSC. Thus, four-
digit resolution HLA-DRB1 genotyping was performed in 356 PSC patients and 366 healthy
controls. Sequence information was used to assign which amino acids were encoded at all pol-
ymorphic positions. In stepwise logistic regressions, variations at residues 37 and 86 were inde-
pendently associated with PSC (P 5 1.2 3 10
232 and P 5 1.8 3 10
222 in single-residue
models, respectively). Three-dimensional modeling was performed to explore the effect of
these key residues on the HLA-DR molecule. This analysis indicated that residue 37 was a
major determinant of the electrostatic properties of pocket P9 of the peptide-binding groove.
Asparagine at residue 37, which was associated with PSC, induced a positive charge in pocket
P9. Tyrosine, which protected against PSC, induced a negative charge in this pocket. Consist-
ent with the statistical observations, variation at residue 86 also indirectly inﬂuenced the elec-
trostatic properties of this pocket. DRB1*13:01, which was PSC-associated, had a positive P9
pocket and DRB1*13:02, protective against PSC, had a negative P9 pocket. Conclusion:T h e
results suggest that in patients with PSC, residues 37 and 86 of the HLA-DRb chain critically
inﬂuence the electrostatic properties of pocket P9 and thereby the range of peptides presented.
(HEPATOLOGY 2011;53:1967-1976)
See Editorial on Page 1798
G
enetic predisposition inﬂuences the develop-
ment of primary sclerosing cholangitis (PSC).
1
The co-occurrence of inﬂammatory bowel dis-
ease and classical autoimmune diseases in patients with
PSC suggests that loss of immune tolerance contributes
to the pathogenesis. The strongest genetic risk factors in
PSC are found in the human leukocyte antigen (HLA)
complex at chromosome 6p21.
2 Many of the genes in
this region are immune-related, and variants tend to
be inherited together on extended haplotypes, i.e., they
are in strong linkage disequilibrium (LD). Deciphering
the contribution of the various genes in the region is a
major challenge in disease genetics.
Abbreviations: AH, ancestral haplotype; HLA, human leukocyte antigen; LD, linkage disequilibrium; PSC, primary sclerosing cholangitis.
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1967As for most HLA-associated diseases, a multitude of
HLA class I and class II gene associations have been
reported in PSC, most consistently for alleles that are
components of the extended ancestral haplotypes
AH8.1 (i.e., HLA-B*08-DRB1*03 [serological DR3])
and AH7.1 (i.e., HLA-B*07-DRB1*15 [serological
DR2]), along with various less conserved HLA class II
haplotypes, namely, DRB1*13:01, DRB1*04, and
DRB1*07.
3-6 In genome-wide association studies,
2,7
strong associations near HLA-C, HLA-B, and MICA
suggest a role for these loci in modifying PSC risk.
The mechanism could involve an effect of alleles car-
ried by the AH8.1 and AH7.1 haplotypes on the acti-
vation level of natural killer cells and T cells.
8-11 How-
ever, associations detected for HLA class II haplotypes
appear to have a signiﬁcant inﬂuence on PSC, in addi-
tion to the effect of HLA class I.
7
The class II genes encode heterodimers consisting of
an a and a b chain (e.g., the HLA-DR molecule is
encoded by HLA-DRA and HLA-DRB1) which present
peptides to CD4-positive T cells. The sequences
encoded by the second exon of class II genes deter-
mine the properties of the peptide-binding groove. In
several autoimmune diseases HLA class II associations
have been attributed to particular amino acids in the
molecule that critically determine the binding of dis-
ease-speciﬁc antigen(s). One example is the protective
effect in type 1 diabetes of HLA-DQb1 chains with
aspartic acid in residue 57,
12 which induces distinct
characteristics of the peptide-binding groove of the
HLA-DQ molecule.
13 Determination of the structural
and electrostatic properties of the molecules associated
with disease may help in identifying the disease mech-
anism. In primary biliary cirrhosis and autoimmune
hepatitis, speciﬁc residues have been suggested to
explain associations with HLA-DRB1 alleles.
14,15 In
PSC, an association with leucine in residue 38 of the
HLA-DRb chain was proposed by Farrant et al.,
16
whereas a later study considered residues 55 and 87 of
the HLA-DQb chain as more likely candidates.
3 A
consistent peptide-binding motif for the class II mole-
cules associated with PSC has not been deﬁned, and
no attempts have been made to model how speciﬁc
amino acids affect the structure and the electrostatic
properties of the peptide-binding groove.
The portal inﬂammation in PSC livers is dominated
by T cells, which seem to exhibit a restricted T-cell re-
ceptor repertoire.
17 It would be of importance to iden-
tify characteristics of the HLA molecules that deter-
mine the speciﬁcity of these T-cell responses. Strong
LD in the HLA class II region makes it difﬁcult to
determine at the genetic level which loci are most rele-
vant. However, several minor observations suggest that
HLA-DRB1 could be the determinant of PSC risk; (1)
The HLA-DQA1 and DQB1 alleles encoded on the
AH8.1 haplotype are associated with PSC only on this
haplotype and not when encoded on different haplo-
types.
4 (2) The protective DRB1*04 haplotypes may
carry different DQB1 alleles.
4 (3) A recent study in Afri-
can-Americans conﬁrms the association with DR13,
18
which in Northern Europe forms the DRB1*13:01-
DQB1*06:03 haplotype,
16 whereas in African-Americans
both DRB1*13:01-DQB1*06:03 and DRB1*13:01-
DQB1*05:02 are common haplotypes.
19 The HLA-
DRB1 association is also more consistent than the associ-
ation with the closely related (paralogous) HLA-DRB3
gene; e.g., PSC-associated HLA-DRB1*13:01 haplotypes
may carry either the HLA-DRB3*01:01 or DRB3*02:02
alleles.
4 Given this background we aimed to explore how
HLA-DRB1 variation affects the molecular characteristics
of HLA-DR and susceptibility to PSC.
Materials and Methods
Subjects. Scandinavian PSC patients (n ¼ 356,
Table 1) were recruited from Oslo University Hospital,
Rikshospitalet, Oslo, Norway, and Karolinska Univer-
sity, Hospital Huddinge, Stockholm, Sweden. Diagno-
sis of PSC was based on accepted criteria with typical
cholangiographic appearance. Ethnically and gender-
matched healthy controls (n ¼ 366) were randomly
selected from the Norwegian Bone Marrow Registry.
All participants gave informed consent. The study was
approved by the Regional Committee for Research
Ethics in South-Eastern Norway and the Ethics Com-
mittee of Karolinska Institutet.
HLA-DRB1 Data. Four-digit HLA-DRB1 geno-
types were available from a previous study.
20 Peptide
sequences of all HLA-DRB1 alleles in IMGT/HLA
database release 2.23 (October 2008) were aligned, and
each individual was assigned two amino acids (one encoded
by each chromosome) for each polymorphic residue.
Statistical Methods. Stepwise logistic regressions
were performed in the statistical package R v2.10.0
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model, entering the count of all amino acids at a given
residue as covariates. A model with all observed com-
binations of amino acids (‘‘genotypes’’) at a given resi-
due entered as covariates was applied to control the va-
lidity of the model. Some combinations of amino
acids were rare and after testing several criteria, combi-
nations with a frequency of n < 2 in cases or controls
at a given residue were grouped in order to avoid
empty cells. In both models the reference was ran-
domly chosen, thus no assumptions were made on
which amino acid or pair of amino acids constituted
high or low risk. Comparisons of allele and carrier
frequencies were performed in Microsoft Excel (Red-
mond, WA) and PASW v. 18 (SPSS, Chicago, IL).
P < 0.05 was considered statistically signiﬁcant. P-val-
ues of novel HLA-DRB1 allele associations were Bon-
ferroni corrected according to the number of alleles
present in the dataset (n ¼ 32).
3D Protein Structure Modeling of HLA-DR Mole-
cules. The atomic coordinates of the most common
HLA-DR molecules were determined using compara-
tive protein structure modeling by satisfaction of spa-
tial restraints as implemented in the MODELLER
computer algorithm.
21 HLA-DR proteins of known
structure suitable as modeling templates were identiﬁed
in the Protein Data Bank (PDB; http://www.rcsb.org/
pdb/) and evaluated for structural quality. Accordingly,
seven structures were selected as templates (PDB
entries: 1KLU, 2G9H, 1D5Z, 1D5M, 2Q6W, 1PYW,
and 2IPK). The amino acid sequences of the target
HLA-DR molecules were obtained from the IMGT/
HLA database. Multiple sequence alignments were per-
formed with CLUSTAL_X v.1.83
22 and manually cor-
rected when indicated. The alignment ﬁles were then
used as input to the MODELLER program. In brief,
MODELLER generates the 3D atomic coordinates of
the target sequences by satisfying spatial restraints,
obtained from the templates, and by CHARMM
23
energy terms enforcing proper stereochemistry. Optimi-
zation is then carried out by employing methods of con-
jugate gradients and molecular dynamics with simulated
annealing.
24 All calculations were performed in the
absence of antigenic peptides to enable direct comparison
of the structural and physiochemical characteristics of the
peptide-binding groove among different molecules. The
stereochemical quality of the modeled structures was
veriﬁed using the PROCHECK
25 and WHAT_
CHECK
26 algorithms and by assessment of Ramachan-
dran plots. In addition, the structures were examined for
protein folding quality using empirical energy potentials
as implemented in the ProSA algorithm.
27 Modeled
coordinate sets are available upon request.
Electrostatic Potential Calculations. The electro-
static potential around the 3D structures was com-
puted by numerically solving the Poisson Boltzmann
equation using the ﬁnite difference method imple-
mented in the DelPhi program within Discovery Stu-
dio 2.1 (Accelrys, San Diego, CA). Essential hydrogens
were added to the structures. To determine the proto-
nation state of titratable amino acid side chains the
titration curves and residue pKa were calculated for
each molecule (dielectric constant of 10 for the protein
interior and 80 for the solvent) and titratable residues
were protonated at a pH of 7.4. The protonated pro-
tein molecule was subsequently used to compute the
electrostatic potential. The low dielectric protein inte-
rior (dielectric constant of 2) was embedded in a high
dielectric continuum environment (water exterior,
dielectric constant of 80). A solution with charged
ions was simulated with an assigned ionic strength of
0.145, typical of the conditions at a pH of 7.4. The
dielectric boundary between the protein and the sol-
vent was deﬁned by calculating the solvent-accessible
surface generated by a rolling probe sphere of 1.4 A ˚
radius. Atomic radii and partial atomic charges were
taken from the CHARMM parameter set.
23 An ion
exclusion layer (Stern layer) for the solvent ions was
deﬁned around the solvent-accessible surface using an
ionic radius of 2 A ˚. The layer has an ionic strength of
0.0 and determines the maximum distance that an ion
can approach the solvent-accessible surface. The system
was mapped into a 3D cubical grid and the electro-
static potential at each grid point was calculated itera-
tively starting from the Debye-Hu ¨ckel boundary con-
ditions. The accuracy of the calculations was improved
by using a method of grid focusing; in the ﬁrst run
the coarse grid was allowed to be ﬁlled by 50% by sol-
ute and the calculated grid point potentials were used
in the second run where the ﬁne grid was ﬁlled by
Table 1. Characteristics of Included Individuals
PSC Healthy Controls
N 356* 366
Male, n (%) 254 (71) 256 (70)
Age at diagnostic cholangiography,
years, median (range)
36 (12-75) —
Concomitant inﬂammatory bowel
disease, n (%)
290† (82) —
Ulcerative colitis/Crohn’s
disease/indeterminate, %
81/12/7 —
Cholangiocarcinoma, n (%) 50 (14) —
Endpoint (tx or death), n (%) 210 (59) —
Follow-up, years, median (range) 10 (0-34) —
*Norway n ¼ 230, Sweden n ¼ 126.
†Missing information about the intestine in three patients.
HEPATOLOGY, Vol. 53, No. 6, 2011 HOV ET AL. 1969solute by 90%. The grid dimensions were set at 251
grid points per axis (spacing 0.3 A ˚ / grid point). The
solvent accessible surface was colored according to its
calculated electrostatic potential and visualized using
the Discovery Studio interface.
Results
Statistical Modeling: Identiﬁcation of Position 37
and 86 in the DRb1 Chain as PSC-Associated Resi-
dues. The amino acid sequence encoded by exon two
of HLA-DRB1 was determined from the genotypes of
each individual. Thirty residues were polymorphic,
i.e., two or more different amino acids were observed
at these positions. In the ﬁrst step, a logistic regression
was performed for each polymorphic residue. The counts
(0, 1, 2) of the observed amino acids were included as
covariates and the overall effect of the residue was tested
with a likelihood ratio test. The strongest PSC associa-
tions were detected for residue 37 (P ¼ 1.2   10
 32,
Table 2). In a second step, two-residue models were ﬁt-
ted containing the amino acid covariates of both the
investigated residue and residue 37 and compared with
the single-residue model of residue 37. The only residue
that remained strongly associated with PSC in these two-
residue models was 86 (Table 2). When performing a
similar two-residue test for additional effects on top of
86, several residues (i.e., also residue 37) were found to
contribute signiﬁcantly (Table 2). No other residues
showed signiﬁcant disease association when included in
three-residue models with residues 37 and 86 (Table 2).
In the logistic models used above the effect of a sin-
gle amino acid was assumed to be additive on the log-
scale: The log-odds ratio of having PSC given two
copies of the amino acid is two times the log-odds ra-
tio when having one copy. The advantage with this
Table 2. Association Analyses Between Amino Acid Variation in the HLA-DRb1 Chain and PSC*
Single-Residue LR Two-Residue LRy Three-Residue LRz
Basic Model: -
Basic Model:
Residue 37
Basic Model:
Residue 86
Basic Model:
Residues 37186
Residue Observed Amino Acids P-value Rank P-value Rank P-value Rank P-value
9 Glu, Lys,Trp 0.051 27 0.59 22 0.0086 20 0.29
10 Glu,Gln,Tyr 2.4   10
 11 14 0.54 21 0.0017 17 0.48
11 Asp,Gly,Leu,Pro,Ser,Val 1.2   10
 18 8 0.23 15 1.7   10
 8 3 0.43
12 Lys,Thr 2.7   10
 12 12 0.64 24 0.00046 14 0.74
13 Phe,Gly,His,Arg,Ser,Tyr 9.6   10
 25 2 0.22 14 2.1   10
 11 2 0.25
14 Glu,Lys 0.0014 20 0.36 17 0.74 28 0.83
16 His,Tyr 3.2   10
 5 17 0.88 29 0.00053 15 0.78
25 Gln,Arg 0.0014 21 0.36 18 0.74 29 0.83
26 Phe,Leu,Tyr 2.6   10
 19 6 0.024 2 3.9   10
 8 4 0.23
28 Asp,Glu,His 2.8   10
 5 16 0.13 8 0.0053 19 0.10
30 Cys,Gly,His Leu,Arg,Tyr 0.00012 18 0.12 7 2.0   10
 5 11 0.20
31 Phe,Ile,Val 0.31 29 0.078 5 0.0046 18 0.12
32 His,Tyr 1.2   10
 21 4 0.38 19 6.6   10
 8 6 0.64
33 His,Asn 1.4   10
 15 11 0.40 20 5.0   10
 8 5 0.31
37 Phe,Leu,Asn,Ser,Tyr 1.2 3 10
232 1 — 3.1 3 10
216 1 —
38 Ala,Leu,Val 0.029 26 0.17 11 0.0014 16 0.14
40 Phe,Tyr 0.77 30 0.17 12 0.52 27 0.14
47 Phe,Tyr 2.4   10
 21 5 0.11 6 0.00024 13 0.29
57 Ala,Asp,Ser,Val 2.6   10
 5 15 0.78 26 0.16 22 0.44
58 Ala,Glu 0.00055 19 0.85 28 0.035 21 0.84
60 His,Ser,Tyr 0.0046 24 0.59 23 0.28 24 0.29
67 Phe,Ile,Leu 0.0018 22 0.80 27 0.45 25 0.22
70 Asp,Gln,Arg 0.063 28 0.16 10 0.49 26 0.32
71 Ala,Glu,Lys,Arg 1.4   10
 15 10 0.043 3 5.4   10
 6 8 0.32
73 Ala,Gly 5.5   10
 12 13 0.14 9 1.7   10
 5 10 0.34
74 Ala,Glu,Leu,Gln,Arg 1.7   10
 18 9 0.25 16 9.4   10
 6 9 0.59
77 Asn,Thr 5.8   10
 19 7 0.060 4 4.8   10
 7 7 0.34
78 Val,Tyr 0.023 25 0.77 25 0.25 23 0.20
85 Ala,Val 0.0037 23 0.21 13 7.2   10
 5 12 0.13
86 Gly,Val 1.8   10
 22 3 2.0 3 10
25 1 ——
*Stepwise logistic regressions were performed assuming an ‘‘allele dosage’’ effect.
†P-values of likelihood ratio tests of whether residue n improves the logistic regression model when added to a model with one other residue (37 or 86).
‡P-values of likelihood ratio tests of whether residue n improves the model when added to a model with both residues 37 and residue 86.
LR: likelihood ratio; Rank: residue rank according to P-value, lowest P-value is highlighted in bold.
1970 HOV ET AL. HEPATOLOGY, June 2011model is that it keeps the number of covariates to a
minimum, leading to more powerful tests as long as the
model assumptions are approximately true. In order to
conﬁrm the results obtained with this model, we also
performed regressions where we allowed each observed
combination (‘‘genotype’’) of amino acids to have a
potential effect. In these ‘‘genotype’’ model analyses, res-
idue 37 remained the most signiﬁcantly PSC-associated
residue (P ¼ 6.9   10
 32, Table 3), with an independ-
ent contribution from residue 86 still observed (P ¼
1.2   10
 5). Several other residues contributed on top
of residues 37 or 86 in two-residue models, as well as
in three-residue models with both residues 37 and 86
included (Table 3). When inspecting the distribution of
amino acid combinations (‘‘genotypes’’) in the dataset,
it became apparent that the extra associated residues 26,
70, 71, 73, 74, and 77 (Table 3) reﬂected a large num-
ber of patients homozygous for HLA-DRB1*03:01 (n
¼ 62 patients versus n ¼ 3 healthy controls), meaning
that it was not possible to determine the part of HLA-
DRB1*03:01 that confers this additional risk.
In conclusion, residues 37 and 86 were consistent
determinants of PSC susceptibility irrespective of sta-
tistical model, whereas it was difﬁcult to exclude addi-
tional risk associated with other parts of the b chain
encoded by HLA-DRB1*03:01.
Residue 37 Inﬂuences the Electrostatic Properties
of Pocket P9 of HLA-DR. The amino acid frequen-
cies at residues 37 (Table 4) showed that the highest
and lowest risks of PSC were observed for carriers of
asparagine (Asn37) (odds ratio [OR] ¼ 5.7, 95% con-
ﬁdence interval [CI] 4.0-8.0) and tyrosine (Tyr37)
(OR ¼ 0.25, 95% CI 0.18-0.34), respectively.
The speciﬁcity of the peptide-binding groove on an
HLA class II molecule is governed by the properties of
pockets in the groove that accommodate the amino
acid side chains of the bound peptide, typically pock-
ets for peptide residues 1 (pocket P1), 4, 6, and 9.
Residue 37 of the HLA-DRb1 chain is integral to
pocket P9.
28 Figure 1 shows the structural and electro-
static characteristics of pocket P9 on representative
HLA-DR molecules. Signiﬁcantly, HLA-DR carrying
the risk residue Asn37 in the b chain (e.g., HLA-
DRB1*03:01, *09:01, *13:01, *14:02; Fig. 1B) formed
P9 pockets with similar structural architecture and con-
sistently positive surface electrostatic potential (the only
Table 4. Frequencies of Different Amino Acids at HLA-DRb1 Residues 37 and 86
Allele Frequency, n (%) Carrier Frequency, n (%)
Residue Amino Acid PSC Healthy Controls PSC Healthy Controls
37 Asparagine (Asn) 398 (56) 199 (27) 292 (82) 163 (45)
Leucine (Leu) 4 (1) 16 (2) 4 (1) 15 (4)
Phenylalanine (Phe) 35 (5) 67 (9) 34 (10) 62 (17)
Serine (Ser) 192 (27) 208 (28) 162 (46) 175 (48)
Tyrosine (Tyr) 83 (12) 242 (33) 80 (22) 197 (54)
86 Glycine (Gly) 185 (26) 368 (50) 164 (46) 284 (78)
Valine (Val) 527 (74) 364 (50) 335 (94) 282 (77)
Table 3. Summary of Association Analyses Between Amino Acid Variation and PSC Assuming a ‘‘Genotype’’ Model*
Single-Residue LR Two-Residue LRy, Three-Residue LRz
Basic Model: -
Basic Model:
Residue 26
Basic Model:
Residue 37
Basic Model:
Residue 77
Basic Model:
Residue 86
Basic Model:
Residues 37186
Residue P-value P-value P-value P-value P-value P-value
26 6.2x10
 20 — 4.2x10
 7 0.19 1.3x10
 8 4.1x10
 5
37 6.9x10
 32 3.3x10
 19 — 1.5x10
 19 4.8x10
 17 —
70 0.013 0.23 0.023 0.083 0.055 0.036
71 1.6x10
 17 3.8x10
 14 0.00034 3.4x10
 13 7.1x10
 8 0.014
73 1.1x10
 12 0.15 0.00075 0.17 8.1x10
 6 0.0038
74 1.6x10
 18 0.14 6.0x10
 5 0.096 1.3x10
 6 0.00093
77 7.3x10
 21 0.80 8.5x10
 8 — 7.8x10
 9 3.4x10
 6
86 2.0x10
 21 1.3x10
 9 1.2x10
 5 2.2x10
 9 ——
*Stepwise logistic regressions were performed assuming a ‘‘genotype’’ effect, entering all different pairs (combinations) of amino acids at a given residue. Only
residues contributing signiﬁcantly to the model when added to residue 37 and 86 in the three-residue regressions are shown.
†P-values of likelihood ratio tests of whether residue n improves the logistic regression model when added to a model with one other residue (26, 37, 77, or 86).
‡P-values of likelihood ratio tests of whether residue n improves the model when added to a model with both residues 37 and residue 86.
LR: likelihood ratio.
HEPATOLOGY, Vol. 53, No. 6, 2011 HOV ET AL. 1971exception was HLA-DRB1*13:02, further discussed
below). In contrast, HLA-DR molecules expressing the
p r o t e c t i v eT y r 3 7r e s i d u ei nt h eb chain (e.g., HLA-
DRB1*04:01, *10:01, *11:01, *03:25; Fig. 1C) formed
P9 pockets with consistently negative electrostatic poten-
tial. The distinct P9 pocket electrostatic patterns were
conserved both among molecules that differed at several
amino acid sequence positions and between structures
where residue 37 constitutes the only disparity (e.g.,
HLA-DRB1*03:01 and -DRB1*03:25). Interestingly, a
database search for peptides eluted from HLA-DR mole-
cules showed that the presence of Asn37 restricted the
amino acid preferences at position 9 (e.g., only tyrosine,
leucine, and phenylalanine are deﬁned as P9 anchors in
HLA-DRB1*0301), whereas most amino acids may be
P9 anchors in HLA-DRB1*0401 which carries Tyr37
(www.syfpeithi.de).
29
Residue 86 Deﬁnes Opposite Effects of HLA-
DRB1*13:01 and *13:02 on PSC Risk. At the
dimorphic residue 86, the highest risk was observed
for carriers of valine (Val86) (OR ¼ 4.8, 95% CI 2.9-
7.9), whereas glycine (Gly86) appeared protective (OR
¼ 0.25, 95% CI 0.18-0.34). Residue 86 of the HLA-
DRb1 chain is integral to pocket P1.
28 In contrast to
pocket P9, modeling of the P1 pocket of several HLA-
DR molecules showed that the glycine/valine dimor-
phism at residue 86 had a minimal physiochemical
effect. The majority of HLA-DR molecules examined
had P1 pockets with an overall neutral charge (Fig. 2).
Even though a steric effect (i.e., an effect on the volume
of the pocket) imposed by the side chain of Val86 can-
not be excluded, the results of the present analysis argue
against a signiﬁcant role of residue 86 on the choice of
peptide residue accommodated by pocket P1.
Further analysis, however, led to an interesting
observation. As mentioned above, HLA-DR molecules
expressing the risk residue Asn37 in their b chain pos-
sess electropositive P9 pockets, with the exception of
HLA-DRB1*13:02 where an electronegative P9 pocket
was observed (Fig. 3). Notably, when looking at the
allele frequencies, HLA-DRB1*13:02, as opposed to
other Asn37 encoding alleles (like the established PSC
risk allele HLA-DRB1*13:01), was more frequent in
healthy controls than in PSC patients (Pcorrected ¼
0.040, Table 5), suggesting that HLA-DRB1*13:02
may protect against PSC. This statistical observation
Fig. 1. Structure and molecular surface electrostatic potential of pocket P9. (A) The structure and electrostatic potential of HLA-DRB1*03:01.
The area within the frame is depicted in expanded form in (B,C). All structures were superimposed on HLA-DRB1*03:01 and therefore show the
same view. HLA-DR carrying the risk residue Asn37 in the b chain had P9 pockets (arrows) with positive charge (B), whereas molecules expressing
Tyr37 had P9 pockets (arrows) with consistently negative charge (C). Potentials less than  5 kT/e are colored red, those greater than 5 kT/e blue,
and neutral potentials (0 kT/e) are colored white. Linear interpolation was used to produce the color for surface potentials between these values.
1972 HOV ET AL. HEPATOLOGY, June 2011is therefore in agreement with the protective effect asso-
ciated with HLA-DR molecules expressing electronegative
P9 pockets, as shown above for Tyr37 encoding alleles.
Intriguingly, HLA-DRB1*13:02 and DRB1*13:01 have
otherwise overall similar structural architecture and elec-
trostatic properties (Fig. 3) with the main disparity
observed at pocket P9. Because the only amino acid
sequence difference between these alleles is at position 86
it may be suggested that the Gly86Val substitution may
inﬂuence the choice of presented peptides through long-
range electrostatic modiﬁcation of pocket P9.
Discussion
By exploring variation in the amino acid sequence
of the HLA-DRb1 chain in PSC, we show that resi-
dues 37 and 86 distinguish disease susceptibility alleles
and protective alleles. Investigations into the HLA-DR
molecular structure revealed that the electrostatic prop-
erties of pocket P9 are determined by residue 37 and,
indirectly by residue 86, suggesting that the P9 pocket
is crucial for PSC risk.
In the HLA-DR molecule, residue 37 of the b chain
appeared to be a key determinant of the electrostatic
properties of pocket P9, which may be related to dis-
ease risk. The situation is reminiscent of type 1 diabe-
tes, where amino acids at residue 57 of the HLA-DQ
b chain associated with disease risk contribute to a
larger volume of pocket P9 and a positive charge,
allowing, e.g., glutamate residues from insulin peptides
at position 9.
30 In HLA-DR, Asn37 would restrict the
range of amino acids at anchor position 9 of the pep-
tide, and thereby which peptides may be presented.
This is supported by data from peptide elusion experi-
ments, where HLA-DR molecules with Asn37 and
Tyr37 exhibit different ranges of amino acids at P9.
29
Direct experimental observations focusing on pocket
P9 variation and T-cell responses are scarce, but it has
been shown that modiﬁcation of only residue 37 (on
DR4 molecules) is sufﬁcient to alter recognition by
the T-cell receptor, e.g., by neutralizing the T-cell-acti-
vating potential of the peptide-DR-complex.
31,32 It
should therefore be considered highly likely that char-
acteristics of pocket P9 of the HLA-DR molecule facil-
itate particular immune responses.
Pocket P1 of HLA-DR was found to have an overall
neutral electrostatic potential in the present study irre-
spective of whether glycine or valine was present at
position 86. This ﬁts with the observation that this
pocket has a preference for hydrophobic amino acid
side chains, and that the range of amino acids in posi-
tion 1 of presented peptides is largely overlapping.
33,34
However, pocket P1 with Gly86 in the b chain (e.g.,
as encoded by HLA-DRB1*13:02) has a tendency to
accept larger (aromatic) side chains than when Val86 is
present (e.g., encoded by DRB1*13:01); this has been
attributed to the lack of a side chain on glycine allow-
ing for a larger pocket volume.
33,34 A more remarkable
difference between HLA-DRB1*13:01 and DRB1*13:02
Fig. 2. Structure and molecular surface electrostatic potential of
pocket P1. (A) The structure and electrostatic potential of HLA-
DRB1*03:01. The area within the frame is depicted in expanded form
in (B). All structures were superimposed on HLA-DRB1*03:01 and
therefore show the same view. Structural modeling and calculation of
the electrostatic potential at the P1 pocket (arrows) of representative
HLA-DR molecules showed that the Gly/Val dimorphism at position 86
had a minimal physiochemical effect (B). The majority of HLA-DR mol-
ecules examined had P1 pockets with an overall neutral charge. HLA-
DRB1*03:01 and -DRB1*14:01 express Val86 whereas -DRB1*01:01
and -DRB1*04:01 express Gly86. Potentials less than  5 kT/e are
colored red, those greater than 5 kT/e blue, and neutral potentials (0
kT/e) are colored white. Linear interpolation was used to produce the
color for surface potentials between these values.
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substitution at residue 86 affected the electrostatic prop-
erties of pocket P9, in another part of the molecule.
HLA-DRB1*13:02 was the only allele which contributed
to a HLA-DR molecule with a negative pocket P9 with
asparagine at position 37 of the b chain. Intriguingly,
this allele exhibited a signiﬁcantly reduced frequency in
PSC patients. Taken together, our ﬁndings suggest that
the association of residues 37 and 86 with PSC primarily
reﬂects the properties of pocket P9.
Although HLA-DRB1*13:01 is a well-established
PSC risk allele,
4 this study is the ﬁrst identifying HLA-
DRB1*13:02 as a protective allele. This observation was
signiﬁcant even when correcting for multiple compari-
sons. Interestingly, similar contrasting effects have been
observed in autoimmune hepatitis in Latin America,
where risk is associated with HLA-DRB1*13:01 and pro-
tection with DRB1*13:02.
15 HLA-DRB1*13:01 has also
been associated with a protracted course of hepatitis A vi-
rus infection, which has been postulated to be a trigger
of autoimmune hepatitis.
35 To what extent these parallel
observations are relevant for the speciﬁcity of the immune
response in PSC can currently only be speculated.
Given the complexity of the HLA associations in
diseases such as PSC, it is not unlikely that other al-
leles besides the most strongly associated ones modify
Fig. 3. Electrostatic modiﬁcation of pocket P9 by the Gly86-to-Val86 substitution. The structure and electrostatic potential of the peptide-bind-
ing groove is shown for (structures were superimposed) HLA-DRB1*13:01 (left ﬁgures) and -DRB1*13:02 (right ﬁgures); these molecules have a
single amino acid sequence difference at position 86 (Val86 and Gly86, respectively). HLA-DRB1*13:02 has an electronegative pocket P9 de-
spite the presence of Asn at position 37, suggesting a long-range effect of the Val86-to-Gly86 substitution. The molecular surface is colored
according to the calculated electrostatic potential, as for Figs. 1 and 2.
Table 5. Frequency of HLA-DRB1Alleles Encoding Asn37
PSC (2n5712)
Healthy Controls
(2n5732)
OR (95%CI)* P-valuey Residue 86 Allele n (%) n (%)
03:01 254 (36) 106 (14) 3.3 (2.5-4.2) 1.3   10
 20 Val
09:01 12 (2) 6 (1) 2.0 (0.8-5.0) 0.14 Gly
13:01 117 (17) 47 (6) 2.8 (2.0-4.1) 2.0   10
 9 Val
13:02 15 (2) 39 (5) 0.4 (0.2-0.7) 0.0013‡ Gly
14:02 0 (0) 1 (0) 0.3 (0.0-3.8) 1.0 Gly
*Calculated with Woolf’s formula with Haldane’s correction.
†Not corrected. Calculated with chi-square tests or Fisher’s exact test where appropriate.
‡Pcorrected ¼ 0.040.
OR ¼ odds ratio. CI ¼ conﬁdence interval.
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PSC evaluated selected residues encoded by haplotypes
associated with disease,
3,16 and suggested that the pres-
ence of leucine at position 38 (Leu38) of the b chain
may confer risk. Leu38 is rarely present in DRb1
(most often encoded by DRB1*12 alleles). An explana-
tion for the conﬂicting results is that the previous
studies included alleles at both the HLA-DRB1 locus
as well as those at other, paralogous, HLA-DRB loci.
Several HLA haplotypes carry a second HLA-DRB
gene besides HLA-DRB1, e.g., HLA-DRB1*03:01 and
*13:01 haplotypes typically also carry an allele encoded
by HLA-DRB3; DRB1*04 and *07:01 carry an allele
encoded by HLA-DRB4, and the DRB1*15:01 haplo-
type carries an allele encoded by HLA-DRB5.T h e s eb
chains couple with DRa and also have a role in antigen
presentation.
36 They are generally observed at several-
fold lower expression levels than DRb1.
37,38 However,
in diseases where the second DRB gene has been shown
to be of actual relevance, the association seems to be
speciﬁc to the gene in question and not due to shared
sequence motifs with DRB1.
39–41 These facts, along
with the more consistent PSC associations with HLA-
DRB1 rather than HLA-DRB3,
4 make it likely that the
present focus on DRB1 is valid, even though an effect
of other DRB loci cannot be formally ruled out at this
stage.
Given the LD in the HLA complex, we cannot
exclude the possibility that causal variants at other loci
may be associated with the distribution of amino acids
observed at given positions in HLA-DRb1. The strong
LD is particularly important in relation to the neigh-
boring HLA-DQ genes and HLA-DRB paralogs, but it
is also difﬁcult to formally exclude an association with
the nearby BTNL2 gene, which has been associated
with inﬂammatory bowel disease,
42 or even genetic
variants further away. When applying a ‘‘genotype’’
model, in addition to residue 37 and 86 we could not
exclude a residual association that could be attributed
to being homozygous for HLA-DRB1*03:01. This
may be speculated to relate to effects of a recessive var-
iant outside HLA-DRB1,
4 potentially related to the
AH8.1 haplotype which is associated with multiple
autoimmune diseases and probably contains several
genetic variants in strong LD contributing to disease.
43
In conclusion, this study shows that variation in
PSC associated residues encoded by HLA-DRB1 impose
distinct structural and physiochemical characteristics on
the HLA-DR peptide-binding groove, suggesting that
PSC risk molecules likely present a restricted peptide
repertoire. The ﬁndings are highly relevant for and im-
portant to evaluate in future experimental studies of
antigen presentation in PSC. The amino acid sequence
and structural observations did not apply uniformly to
all PSC patients, suggesting multiple pathogenetic
mechanisms, as might be expected for a disease with
the clinical heterogeneity observed in PSC.
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